跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT04944979
NCT04944979进行中（未招募）3 期

A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID)

Kedrion S.p.A.24 个研究点 分布在 6 个国家目标入组 30 人开始时间: 2021年3月31日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
进行中（未招募）
发起方
入组人数
30
试验地点
24
主要终点
Incidence Rate of Acute Serious Bacterial Infections
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
2 Years 至 16 Years（Child）
性别
All
接受健康志愿者
否

入选标准

  • •Written informed consent/assent obtained from the patient and his/her parent(s) or legally acceptable representative indicating that they understand the purpose of and procedures required for the study and are willing to participate in it.
  • •Confirmed clinical diagnosis of a PID as defined by 2017 International Union of Immunological Societies (IUIS) Phenotypic Classification for Primary Immunodeficiencies (Bousfiha A, 2018 - and subsequent revisions) and The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity (Seidel MG et al., 2019 - and subsequent revisions) and requiring treatment with IVIg. Documented agammaglobulinemia (defined as the total absence of one or more classes of antibodies) or hypogammaglobulinemia (defined as low levels of one or more classes [i.e., at least 2 standard deviations under the mean level per age]).
  • •(NOTE: IVIg treatment is generally requested in the absence of IgG independently from whether other antibodies are absent).
  • •Male or female, age from 2 up to < 16 years, at the time of screening.
  • •Received 200 to 800 mg/kg of a commercially available IVIg therapy in the range of 21- or 28-day intervals (±3 or ±4 days, respectively) for at least 3 infusions prior to screening.
  • •(NOTE: Other IVIgs will be prohibited after ICF signature and until study end, week 51/52).
  • •At least 2 documented IgG trough levels while receiving an IVIg, of ≥ 6 g/L obtained at 2 infusions within 12 months (1 must be within 6 months) prior to ICF signature.
  • •Patient and his/her parent(s)/legal guardian(s) are willing to comply with all requirements of the protocol.
  • •Females of child-bearing potential with a negative pregnancy test (serum or urine) and who agree to employ adequate birth control measures during the study, such as:
  • •sexual abstinence, to be evaluated in relation to the preferred and usual lifestyle of the subject;
  • •male or female condom with or without spermicide;
  • •cap, diaphragm or sponge with spermicide;
  • •progestogen-only oral hormonal contraception, if already used in the past on medical prescription.
  • •Adequate birth control measures should be maintained throughout the study under parental control.
  • •Authorization to access personal health information.
  • •Patients previously participating in a clinical trial with another experimental IVIg may be enrolled if they have received stable commercially available IVIg therapy for at least 3 infusions (21 or 28 days) prior to screening.
  • •Patients currently on treatment with any subcutaneous immunoglobulin (SCIG) can be enrolled if they are switched to stable commercially available IVIg therapy for at least 3 infusions (21 or 28 days) prior to screening.
  • •Males or females with a body weight greater than or equal to 15 kg (≥ 15 kg).

排除标准

  • •Newly diagnosed PID and naïve to IgG replacement therapy.
  • •Dysgammaglobulinemia (defined as a deficiency in one or more classes of antibodies, but not severe enough to require substitutive therapy) or isolated IgG subclass deficiency, or profound primary T cell deficiency (defined as the absence or severe reduction of T lymphocytes [CD3+ < 300 cell/mm3] and an absent or particularly low proliferative response [10% of the lower normal range] to phytohaemagglutinin P [PHA]).
  • •History of severe or serious reactions or hypersensitivity to IVIg or other injectable forms of IgG.
  • •History of thrombotic events including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks, or myocardial infarction, as defined by at least 1 event in patient's lifetime.
  • •IgA deficiency with documented antibodies to IgA.
  • •Received blood products that have not undergone viral inactivation measures within 12 months prior to ICF signature.
  • •Significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia.
  • •An acute infection as documented by culture or diagnostic imaging and/or a body temperature ≥38.5 °C (≥101.3 °F) within 7 days prior to screening.
  • •Acquired immunodeficiency syndrome (AIDS) and/or hepatitis B/C active disease at ICF signature.
  • •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times of the upper limit of normal for the laboratory designated for the study.
  • •Using an implanted venous access device.
  • •Moderate or severe anemia, defined according to patient's age as shown in the following table (World Health Organization, 2011) or persistent severe neutropenia (≤ 500 neutrophils per mm3) or persistent lymphopenia of less than 500 cells per microliter.
  • •A severe chronic condition such as renal failure [defined as abnormalities in kidney structure or function that are present for more than 3 months and have health implications. The disease is classified on the basis of cause and category of glomerular filtration rate (GFR) (G1 to G5) and albuminuria (A1 to A3) (KIDIGO, 2017). See the following table], congestive heart failure (New York Heart Association III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity, or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
  • •History of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to ICF signature.
  • •History of pharmacoresistant epilepsy or multiple episodes of migraine (defined as at least 1 episode within 6 months of ICF signature) not controlled by medication.
  • •Patient must not be receiving the following medication from at least 30 days prior to ICF signature:
  • •Steroids, inhaled, oral or parenteral, at a daily dosage of ≥ 0.15 mg/kg/day of prednisone or equivalent).
  • •Other immunosuppressive drugs (including monoclonal antibodies) or chemotherapy.
  • •Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
  • •Participated in another clinical study within 30 days prior to ICF signature.
  • •Active drug or alcohol abuse or history of drug or alcohol abuse within the 6 months before screening.
  • •Direct relative of an employee of the CRO, the study site, or Kedrion.
  • •Previously treated under this protocol.
  • •Unable to provide informed consent.
  • •Patients with any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives or the patient's participation in this trial.
  • •Patients with Hypersensitivity to the active substance or to any of the excipients.

研究组 & 干预措施

Experimental: Kedrion IVIG 10%

Experimental

Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.

干预措施: Kedrion IVIG 10% (Biological)

结局指标

主要结局

Incidence Rate of Acute Serious Bacterial Infections

时间窗: From Baseline (Day 1) up to week 51/52

Incidence rate (i.e., the mean number of acute serious bacterial infections per patientyear) of acute serious bacterial infections (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) according to pre-specified criteria).

次要结局

  • Incidence rate (i.e., the mean number per patient-year) of any infection other than acute serious bacterial infections(From day 1 to week 51/52)
  • Days of hospitalizations due to infection(From day 1 to week 51/52)
  • Duration of patients on antibiotics for the treatment of any kind of infection(From day 1 to week 51/52)
  • Days of missed work/school/other major activities due to infections(From day 1 to week 51/52)
  • Number of Adverse Events (%) and proportion of patients experiencing at least one Adverse Event (AE)(From Baseline (Day 1) up to Week 51/52)
  • Number of Serisous AEs (%) and proportion of patients experiencing at least one Serious Adverse Event (SAE)(From Baseline (Day 1) up to Week 51/52)
  • Number of Participants with Changes from Baseline Values in Vital Signs, Physical Examinations, Safety Laboratory Tests (hematology, serum chemistry and urinalysis).(Up to Week 51/52)
  • Serum haptoglobin level(Following infusion 7 for the 28-day infusion schedule and infusion 9 for the 21-day infusion schedule.)
  • Plasma Concentration - Time Curve Of Total Immunoglobulin G (IgG)(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Total Immunoglobulin G (IgG)(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Immunoglobulin G (IgG) subclasses levels (IgG1, IgG2, IgG3, IgG4)(Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule, and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule)
  • Duration of fever episodes(From day 1 to week 51/52)
  • Overall hospitalization days(From day 1 to week 51/52)
  • Pediatric Quality of Life Inventory (Pedsql) Score(At baseline, week 24, and study termination visit)
  • Number and proportion of infusions with one or more infusion (temporally-associated) Adverse Event.(From Baseline (Day 1) up to Week 51/52)
  • Frequency of patients with total Immunoglobulin G (IgG) below 6 g/L(Day 1 up to week 51/52)
  • Anti-tetanus toxoid antibody level(Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule)
  • Serum Immunoglobulin G (IgG) trough levels(Before each infusion of KIg10 and at the study termination visit (Week 51/52))
  • Anti-pneumococcal capsular polysaccharide antibody level(Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule)
  • Anti-Haemophilus influenza type b antibody level(Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule)
  • Incidence rate (i.e. the mean number per patient-year) of fever episodes(From day 1 to week 51/52)
  • Time to Reach the Maximum Plasma Concentration (Tmax) of Total Immunoglobulin G (IgG)(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-Tau) of Total Immunoglobulin G (IgG)(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Elimination Half-Life (t1/2) of Specific IgG Antibodies(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Time to Reach the Maximum Plasma Concentration (Tmax) of Specific Immunoglobulin G (IgG) Antibodies(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Anti-measles antibody level(Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule)
  • Duration of any infection other than acute serious bacterial infections(From day 1 to week 51/52)
  • Incidence rate (i.e. the mean number per patient-year) of patient on antibiotics for the treatment of any kind of infection(From day 1 to week 51/52)
  • The proportion and number of KIg10 infusions for which the infusion rate is decreased due to Adverse Events.(From Baseline (Day 1) up to Week 51/52)
  • The proportion and number of patients with a positive urine hemosiderin test(Following infusion 7 for the 28-day infusion schedule and infusion 9 for the 21- day infusion schedule)
  • Serum Total Immunoglobulin G (IgG) levels, IgG Subclasses Levels, and Selected Specific Antibody Levels(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Elimination Half-Life (t1/2) of Total Immunoglobulin G (IgG)(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Number of related infusion AEs (%) occurring during infusion or within 1, 24, and 72 hours after the end of infusion, and proportion of patients experiencing at least one related infusion AE. at least 1 of such related infusion AE.(From Baseline (Day 1) up to Week 51/52)
  • Maximum Observed Plasma Concentration (Cmax) Of Total IgG(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Plasma Concentration-Time Curve Of Specific Immunoglobulin G (IgG) Antibodies(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-Tau) of Specific Immunoglobulin G (IgG) Antibodies(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • The proportion and number of patients with a positive Coomb's test(Following infusion 7 for the 28-day infusion schedule and infusion 9 for the 21-day infusion schedule)
  • Volume Of Distribution of Specific Immunoglobulin G (IgG) Antibodies(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Maximum Observed Plasma Concentration (Cmax) of Specific Immunoglobulin G (IgG) Antibodies(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC[0-inf]) of Total Immunoglobulin G (IgG)(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Elimination Rate Constant of Total Immunoglobulin G (IgG)(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Volume of Distribution of Total Immunoglobulin G (IgG)(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Specific Immunoglobulin G (IgG) Antibodies(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Elimination Rate Constant of Specific Immunoglobulin G (IgG) Antibodies(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))
  • Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-inf]) of Specific Immunoglobulin G (IgG) Antibodies(Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule))

研究者

发起方
Kedrion S.p.A.
申办方类型
Industry
责任方
Sponsor

研究点 (24)

Loading locations...

相似试验

已完成
3 期
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID PatientsPrimary Immunodeficiency Disease
NCT03961009Kedrion S.p.A.47
已完成
3 期
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)Primary ImmunodeficiencyAgammaglobulinemiaHypogammaglobulinemiaAntibody Deficiency
NCT01581593Kedrion S.p.A.45
招募中
1 期
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.Advanced Malignant Solid Tumours
NCT06600022Sinocelltech Ltd.441
尚未招募
1 期
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.Advanced Malignant Solid Tumours
NCT06304818Sinocelltech Ltd.515
已完成
1 期
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarcinomaGastric AdenocarcinomaAdvanced Solid TumorsGastroesophageal Junction Adenocarcinoma
NCT03852251Akeso338